2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162940
    MerTK/Axl-IN-1 3036009-40-9 98%
    MerTK/Axl-IN-1 (Compound A-910) is a potent and selective dual MerTK/Axl inhibitor, with IC50s of 4.2 and 8.8 nM in Ba/F3, and 0.2 and 0.9 nM in HTRF. MerTK/Axl-IN-1 results in pMerTK inhibition in vivo. MerTK/Axl-IN-1 has long half-life, high oral exposure and bioavailability.
    MerTK/Axl-IN-1
  • HY-163035
    EM-163 1206480-93-4
    EM-163 is a summative BB-Loop analog. EM-163 can alleviate inflammation and prevent death from toxic shock by targeting the TIR domain of MyD88. EM-163 can be used in the study of SEB poisoning (SEB: Staphylococcal enterotoxin B).
    EM-163
  • HY-163041
    PD-1/PD-L1-IN-36 2714327-65-6 98.0%
    PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC50: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy.
    PD-1/PD-L1-IN-36
  • HY-163101
    CP-96021 139401-43-7 98.04%
    CP-96021 is an orally active dual leukotriene D4 (LTD4) and platelet activating factor (PAF) receptor antagonist, featuring a guinea pig LTD4 receptor Ki of 34 nM and a rabbit PAF receptor Ki of 37 nM. CP-96021 blocks ligand binding to its target receptors, inhibits ligand-induced bronchoconstriction, and inhibits antigen-triggered airway obstructive effects. CP-96021 can be used for the research of asthma.
    CP-96021
  • HY-163480
    PF-06835375 2796997-12-9
    PF-06835375 is a selective, humanized CXCR5-targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases.
    PF-06835375
  • HY-163542
    Pneumolysin-IN-1 330842-49-4 98.08%
    Pneumolysin-IN-1 (compound PB-3) is a targeted small molecule inhibitor of Pneumolysin (PLY) (IC50=3.1 µM). Pneumolysin-IN-1 is a pore blocking agent and an anti-virulence factor. Pneumolysin-IN-1 can be used to study the infection caused by Streptococcus pneumoniae.
    Pneumolysin-IN-1
  • HY-164670
    D228 2676188-98-8 99.77%
    D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS (HY-116282C)-induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling.
    D228
  • HY-16718A
    Dagrocorat hydrochloride 1044535-61-6 99.85%
    Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat hydrochloride is also a time-dependent reversible inhibitor of CYP3A (IC50=1.3 μM in human liver microsomes) and CYP2D6 (Ki=0.57 μM in human liver microsomes). Dagrocorat hydrochloride can be used for the research of rheumatoid arthritis.
    Dagrocorat hydrochloride
  • HY-16729A
    Relenopride hydrochloride 1221416-42-7 99.85%
    Relenopride (YKP10811) hydrochloride is a specific and selective 5-HT4 receptor agonist (Ki=4.96 nM). Relenopride hydrochloride has 120-fold and 6-fold lower affinity, respectively, for 5-HT2A (Ki=600 nM) and 5-HT2B receptors (Ki=31 nM) than for 5-HT4. Relenopride hydrochloride increases gastrointestinal (GI) motility.
    Relenopride hydrochloride
  • HY-168498
    GJG057 2761767-18-2 98.82%
    GJG057 is a selective, orally active inhibitor for leukotriene C4 synthase (LTC4S) with an IC50 of 44 nM. GJG057 exhibits anti-inflammatory activity in mouse skin inflammation model and mouse asthma model.
    GJG057
  • HY-168582
    IL-17-IN-2 3058278-46-6 98%
    IL-17-IN-2 (Example 51) is a potent inhibitor of IL-17, with the IC50 of < 0.4 μM in HTRF and NHK assay.
    IL-17-IN-2
  • HY-168764
    C16 Galactosylceramide 34324-89-5 98.00%
    C16 Galactosylceramide is a sphingolipid compound. C16 Galactosylceramide participates in the physiological processes of lipid metabolism and immune regulation in cells. C16 Galactosylceramide can be used in the study of diabetes.
    C16 Galactosylceramide
  • HY-169933
    NEK7-IN-1 2738569-12-3 98%
    NEK7-IN-1 (Compound I-15) is the inhibitor for NIMA-related kinase 7 NEK7 with IC50 <100 nM. NEK7-IN-1 inhibits the IL-1β release with IC50 <50 nM.
    NEK7-IN-1
  • HY-169949
    TAK-756 98%
    TAK-756 is a selective transforming growth factor β-activated kinase 1 (TAK1) inhibitor with a target pIC50 of 8.6. TAK-756 can inhibit TAK1 autophosphorylation and downstream NF-κB phosphorylation, suppress the production of inflammatory and catabolic factors such as MMP-3 and IL-6. TAK-756 exhibits anti-inflammatory effects in a rat joint inflammation model. TAK-756 can be used for the research of inflammatory joint disease, osteoarthritis.
    TAK-756
  • HY-170772
    Dual Cathepsin L/JAK-IN-1 2450279-41-9 98.47%
    Dual Cathepsin L/JAK-IN-1 (Compound A8) is a dual inhibitor of Cathepsin L (CTSL) and JAK, with IC50 values of 0.68 μM, 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for CTSL, JAK1/2/3, and TYK2, respectively. Dual Cathepsin L/JAK-IN-1 effectively blocks the activation of the MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. Dual Cathepsin L/JAK-IN-1 can be used in research on acute lung injury (ALI).
    Dual Cathepsin L/JAK-IN-1
  • HY-171342
    Mal-C2-amide-C10-tri-GalNAc 2893765-20-1
    Mal-C2-amide-C10-tri-GalNAc (Compound 1226) is an asialoglycoprotein receptor (ASGPR) binding ligand fragment and a component of lysosome-targeted bifunctional molecules. Mal-C2-amide-C10-tri-GalNAc promotes the sequestration and degradation of extracellular target molecules in lysosomes. Mal-C2-amide-C10-tri-GalNAc is used in the research of autoimmune diseases.
    Mal-C2-amide-C10-tri-GalNAc
  • HY-171572
    Atezolizumab-MMAE 98.04%
    Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model.
    Atezolizumab-MMAE
  • HY-171894
    AXSP0056BS
    AXSP0056BS is an allosteric GTP cyclohydrolase I (GCH1) inhibitor with an IC50 of 4 μM. AXSP0056BS is applicable to the research of neuropathic and inflammatory pain disorders.
    AXSP0056BS
  • HY-172774
    TRPV1 antagonist 10 896584-55-7 98.54%
    TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC50 = 33.06 nM), moderate to weak URAT1 (IC50 = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain.
    TRPV1 antagonist 10
  • HY-172903
    Nav1.8-IN-16 98%
    Nav1.8-IN-16 (Compound (R)-40) is an orally active and selective hNaV 1.8 inhibitor (IC50: 5.9 nM). Nav1.8-IN-16 exerts analgesic effects by blocking NaV1.8 channels without significantly affecting other NaV subtypes or hERG channels. Nav1.8-IN-16 exhibits dose-dependent analgesic effects in postoperative pain and inflammatory pain models and can be used in pain-related research.
    Nav1.8-IN-16
Cat. No. Product Name / Synonyms Application Reactivity